Abstracts and Publication

Call for Abstracts and Proceedings

Authors are invited to submit a one-page abstract. A template will be available online. Abstracts will be accepted only, if the template format is used accurately. Each submission will be peer-reviewed and, if accepted, published in an online open-access proceedings. Each contribution is assigned a DOI.

Additionally, a printed version of the book of abstracts will be available at the symposium.

To be included in the conference publication, a submission of your abstract (latest on Aug 05, 2018) and presentation of your research at the conference (as a talk or poster) is mandatory.

www.rab-symposium.org/publication

Information

Scientific Chair
Prof. Dr. Gabriela Riemekasten
E-Mail: gabriela.riemekasten@uksh.de

Scientific Office
Dr. Anja Kerstein
E-Mail: anja.kerstein@uksh.de
T: +49 451 500-50866

Host and Organization
Infinite Science GmbH
E-Mail: info@gpcr-symposium.de
T: +49 451 5853-29

Venue and Accommodation
Radisson Blu Senator Hotel
Willy-Brandt-Allee 6, 23554 Lübeck, Germany
T: +49 451-14
www.senatorhotel.de

The Hotel offers a limited number of rooms at our special rate. Please indicate the key GPCR when booking a room.

Conference Ticket of Deutsche Bahn
Special prices are offered. Further information and online booking: www.infinite-science.de/bahn

Registration
Registration is required for first authors of accepted posters or talks. If you are the first author of an accepted abstract, your registration cannot be refunded. If the first author is unable to attend the meeting and would like to appoint a substitute presenter, contact us by email for final approval. Full payment of the registration fee must be made at the time of registration by credit card (Visa, MasterCard), SofortÜberweisung or within 7 days by bank transfer. Early registration fee needs to be paid by July 15, 2018. Please register online at:
www.rab-symposium.org/registration

Registration fee

<table>
<thead>
<tr>
<th></th>
<th>until 15.07.18</th>
<th>from 16.07.18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full registration</td>
<td>325 €</td>
<td>375 €</td>
</tr>
<tr>
<td>Student registration*</td>
<td>145 €</td>
<td>165 €</td>
</tr>
<tr>
<td>Social event</td>
<td>65 €</td>
<td>65 €</td>
</tr>
</tbody>
</table>

* Only valid up to the age of 27 years, student ID required upon registration

Cancellation policy
For cancellations made by Aug 15, 2018, your registration fee will be refunded less a 70 € cancellation fee. No refunds will be given for cancellations made after Aug 15, 2018.

www.rab-symposium.org/transparency

Sponsors

The 2nd Symposium on Functional Autoantibodies Targeting G-Protein-Coupled Receptors is kindly supported by:

EUROIMMUN
a珀kinElmer company

Call for papers

2nd Symposium on
Regulatory Autoantibodies Targeting G-Protein-Coupled Receptors
September 28 – 30, 2018
12 CME credit points

www.rab-symposium.org

LÜBECK 2018

Disclosure of cooperation:
www.rab-symposium.org/sponsors

Scientific Committee

Prof. Dr. Gabriela Riemekasten
Director, Department of Rheumatology and Clinical Immunology; Universitätsklinikum Schleswig-Holstein and Universität zu Lübeck

Prof. Dr. Yehuda Shoenfeld
Head of the Center of Autoimmunity at Sheba Tel Ha Shomer Hospital Tel Aviv University, Israel

Prof. Dr. Fritz Boege
Director, Central Institute for Clinical Chemistry and Laboratory Diagnostics Universitätssklinikum Düsseldorf

Prof. Dr. Duska Dragun
Head of the nephrology research laboratory at the Charité Campus Virchow-Klinikum Berlin

Call for Abstracts and Proceedings

Authors are invited to submit a one-page abstract. A template will be available online. Abstracts will be accepted only, if the template format is used accurately. Each submission will be peer-reviewed and, if accepted, published in an online open-access proceedings. Each contribution is assigned a DOI.

Additionally, a printed version of the book of abstracts will be available at the symposium.

To be included in the conference publication, a submission of your abstract (latest on Aug 05, 2018) and presentation of your research at the conference (as a talk or poster) is mandatory.

www.rab-symposium.org/publication
Dear Sir or Madam, dear colleagues,

It is a great pleasure to announce the second symposium on regulatory autoantibodies targeting G-protein-coupled receptors (GPCRs) in Lübeck. GPCRs are involved in a variety of physiological and pathophysiological processes. So far, much effort has been made on anti-GPCR drug discovery with a focus on the development of small molecules and monoclonal antibodies for the treatment of cancer, infection, metabolic disorders or inflammatory diseases. Recently, functional autoantibodies directed against GPCRs were identified in various diseases associated with pathogenesis, uncovering a potential new field of therapeutic intervention. Thus, the aim of this symposium is to combine the current knowledge on the role of GPCRs in different pathologies, their mode of action and state-of-the-art research techniques to identify common fundamental pathways that can be transferred to other disease entities with similar manifestations.

I cordially invite you to participate in this inspiring symposium with outstanding speakers from the field of GPCR research and constructive discussions as well as poster sessions. I look forward to welcome you to the beautiful Hanseatic City of Lübeck and encourage you and your colleagues to contribute to this exciting meeting.

Prof. Dr. Gabriela Riemekasten
Director
Department of Rheumatology and Clinical Immunology
Universitätsklinikum Schleswig-Holstein
Universität zu Lübeck

<table>
<thead>
<tr>
<th>Welcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
</tr>
</tbody>
</table>

**Friday, September 28, 2018**

16:00 - 20:00
Registration

17:00 - 18:30
Welcome and opening lectures
Welcome note by the University President
Gabriele Gillesen-Kaesbach
Welcome note by the Symposium’s Chair
Gabriela Riemekasten
Challenges in the research of anti-GPCR ab I
Duska Dragun
Challenges in the research of anti-GPCR ab II
Martin Lohse

18:40 - 20:30
Get-together

**Saturday, September 29, 2018**

09:00 - 10:30
Anti-GPCR ab: advantages, pitfalls and problems in the diagnosis
   Functional ab causing psychiatric manifestations:
   Lessons need to be learned
   Wimda Shaoendt
   Ab signatures in autoimmune and non-autoimmune diseases
   Gabriela Riemekasten
   Lessons from TSHR ab: pitfalls and challenges in their diagnostic
   Simon Lyttle
   Talks from selected abstracts

10:30 - 11:00
Coffee break

11:00 - 12:30
Are anti-GPCR ab pathogenic?
ß-adrenergic receptor ab: pitfalls in the diagnostic and in studying ab effects
Fritz Boege
Novel targets in the diagnosis of autoimmune and non-autoimmune diseases
Harald Heidecke
Anti-AT1R ab and autoimmunity to GPCR as cause or contributor to skin fibrosis and intestinal lung disease
Xinhua Yu
Monoclonal anti-AT1R ab from a Ssc mouse model: evaluation of their functions
Frank Petersen
Talks from selected abstracts

12:30 - 13:30
Lunch break

13:30 - 14:30
Poster session

14:30 - 16:00
Signaling of anti-GPCR ab: can we identify novel targets?
Signaling and GPCR biology using cell models
Aurèle Philippe
Lessons from dermatology: anti-Dsg1/3 und anti-BP180-induced signaling
Ralf Ludwig
Role of antibodies against PAR-1 and PAR 2 in different diseases
Nusen Gatar
Talks from selected abstracts

16:00 - 16:30
Coffee break

16:30 - 18:00
Anti-GPCR ab as marker for diseases and therapeutic responses
Antibodies against complement receptors: impact on pathophysiology
Christian Karsten
Anti-GPCR ab in atherosclerosis
Zouhair Aherbhou
Immunoadsorption in Vascular Dementia - a novel approach to Alzheimer’s Disease?
Hans Grab
First results of the prospective ETICS-Study: inflammation rather than ischemia triggers the development of cardiac GPCR-autoantibodies
Roland Jahn
Talks from selected abstracts

**Sunday, September 30, 2018**

09:00 - 10:30
The difficulty of applying new treatment options in outpatient and clinical patient care.
   Chronic Fatigue-Syndrom und Apherese
   Carmen Scheiban-Kogan
   The DNA-based therapeutic agent BC 007 completely neutralizes agonistic autoantibodies directed against 1-adrenoreceptors: results of a phase 1 trial
   Nino-Berte Becker
   Talks from selected abstracts

10:30 - 11:00
Coffee break

11:00 - 12:15
Summary and round table discussion, closing remarks
30 years of functional anti-GPCR ab: how to come into the clinical practice? What is missing to convince others?
   Closing remarks
   Gabriela Riemekasten